TransCode Therapeutics, Inc., an RNA oncology company, has announced that it has regained compliance with Nasdaq's listing standards, ensuring that its stock will continue to be listed and traded on the Nasdaq Stock Market. The scheduled Nasdaq Hearing Panel on June 25, 2024, has been cancelled as a result of this compliance. The company is under Nasdaq panel monitoring until January 26, 2025. This news follows recent positive developments, including promising blood test results from a Phase 0 clinical trial and FDA authorization for a Phase 1 study. Interim CEO and CFO Tom Fitzgerald expressed confidence in the company's trajectory and noted that a reverse stock split is not anticipated due to the share price exceeding the $1.00 minimum bid price required by Nasdaq. TransCode focuses on developing RNA therapeutics for metastatic cancer, with its lead candidate, TTX-MC138, targeting tumors that overexpress microRNA-10b. The company's proprietary TTX nanoparticle platform is central to its strategy for delivering RNA-based treatments.

TransCode Therapeutics, Inc., an RNA oncology company, has announced that it has regained compliance with Nasdaq's listing standards, ensuring that its stock will continue to be listed and traded on the Nasdaq Stock Market. The scheduled Nasdaq Hearing Panel on June 25, 2024, has been cancelled as a result of this compliance. The company is under Nasdaq panel monitoring until January 26, 2025. This news follows recent positive developments, including promising blood test results from a Phase 0 clinical trial and FDA authorization for a Phase 1 study. Interim CEO and CFO Tom Fitzgerald expressed confidence in the company's trajectory and noted that a reverse stock split is not anticipated due to the share price exceeding the $1.00 minimum bid price required by Nasdaq. TransCode focuses on developing RNA therapeutics for metastatic cancer, with its lead candidate, TTX-MC138, targeting tumors that overexpress microRNA-10b. The company's proprietary TTX nanoparticle platform is central to its strategy for delivering RNA-based treatments.